Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Ciena EVP & Chief Strategy Officer David M. Rothenstein Sells $870K of Stock
David M. Rothenstein, EVP & Chief Strategy Officer, sold 2,500 shares of Ciena Corp at $348.06 a share, worth $870K in total on Oct 15, 2026. Shares held after the trade: 172,881 (-1.4%).
ConnectM Technology Solutions announced the formation of a Strategic Advisory Board (SAB) to drive growth in its AI energy infrastructure business, specifically targeting data center power, cooling, and storage. The company appointed Ashish Kulkarni, Neil Bhatia, and Jim McCabe to the board to advise on institutional investor positioning, strategic partnerships, and capital allocation.
Werner Enterprises announced preliminary unaudited financial results for the third quarter of 2026, expecting revenue between $946 million and $951 million. Results were negatively impacted by approximately $0.18 per share due to rising fuel prices, driver recruitment investments, and insurance reserve adjustments.
Quartzsea Acquisition Corp shareholders approved an extension of the deadline to complete an initial business combination from October 19, 2026, to February 19, 2027. The company entered into a trust agreement amendment requiring monthly deposits into the trust account of the lesser of $100,000 or $0.033 per public share for each one-month extension. This provides the SPAC with additional time to finalize a merger target while maintaining its trust account structure.
Etoiles Capital Group Co., Ltd completed its domestication, changing its jurisdiction of incorporation from the Cayman Islands to the State of Nevada. As part of the transaction, each Class A ordinary share was automatically converted into one share of common stock of the new Nevada corporation, which continues to trade on Nasdaq under the symbol 'EFTY'.
Data I Signs $13.2M M&A Deal with V-TEK and A&J Programming
Data I/O Corporation has entered into a definitive agreement to acquire V-TEK and A&J Programming. To fund the transaction and provide working capital, the company also announced a $13.25 million private placement of convertible subordinated debentures and common shares at a conversion price of $2.68 per share.
Ultragenyx and Baylor Research Institute entered into a settlement agreement with Navinta LLC to resolve patent litigation regarding DOJOLVI® (triheptanoin). Under the agreement, Navinta is granted a non-exclusive, royalty-free license to market a generic version of the drug starting January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted.
BNB Standard Corporation appointed Alex Odagiu as Chief Executive Officer, effective October 19, 2026, following his service as Interim President. William B. Miller, who served as Interim Principal Executive Officer, will continue in his roles as Chief Financial Officer and principal accounting officer.
Aflac Insider Japan Post Holdings Co. Ltd. Sells $13.5M of Stock
Japan Post Holdings Co. Ltd. sold 113,611 shares of Aflac Inc at $118.19 to $120.31 a share (average $118.53) in 3 transactions, worth $13.5M in total on Oct 15, 2026. Shares held after the trade: 50,134,329 (-0.0%).
Cardinal Infrastructure Group Signs $358M M&A Deal with Hughes Brothers Construction Inc.
Cardinal Infrastructure Group entered into a definitive agreement to acquire Hughes Brothers Construction Inc., a Central Florida heavy civil and site development contractor, for an aggregate purchase price of $357.5 million. The consideration consists of $214.5 million in cash and $143.0 million in Class A common stock, with an additional earn-out potential of up to $162.5 million based on future EBITDA performance. The acquisition establishes a scaled platform for Cardinal in the fast-growing Florida market and is expected to close in the fourth quarter of 2026.
Value
$358M
Counterparty
Hughes Brothers Construction Inc.
“We are excited to welcome Hughes Brothers to Cardinal as we take another important step in our strategy to build the Southeast’s premier site development platform by moving into the fast-growing Central Florida market. Hughes Brothers is an exceptional founder-led business that culturally aligns with what we’re building. They bring an experienced team, both in terms of field personnel and corporate leadership, longstanding customer relationships, h”
Jeremy Spivey, CEO of Cardinal Infrastructure Group
Buckle Insider Bill L. Fairfield Sells $394K of Stock
Bill L. Fairfield sold 8,500 shares of Buckle Inc at $46.38 a share, worth $394K in total on Oct 15, 2026. Shares held after the trade: 44,408 (-16.1%).
IRulya Therapeutics Inc. (formerly Quince Therapeutics) has posted its updated Corporate Presentation for October 2026 to its website and filed it as an exhibit. The presentation provides a strategic overview of the company's product candidates, specifically LAM-001, and outlines planned clinical milestones and market opportunities in pulmonary hypertension and related lung diseases.
OS Therapies announced the initial closing of a warrant exercise inducement and exchange offer, raising $7.2 million in gross proceeds from seven accredited investors. Participating holders exercised warrants at a reduced price of $1.30 per share in exchange for new warrants to purchase an equal number of shares at $1.40. The proceeds will fund regulatory filings and commercial preparation for Herlystic™ in the U.S., U.K., EU, and Australia.
Bitmine Immersion Technologies announced that its total crypto, cash, and marketable securities holdings have reached $15.1 billion. The company now holds 6.04 million ETH tokens, representing 4.9% of the total ETH supply, and continues to execute its strategy of weekly crypto accumulation.
Tron Inc. announced its successful election as one of the 27 Super Representative (SR) nodes on the TRON network, ranking #27 with 0.76 billion delegated TRX tokens. As an SR, the company will participate in block production and transaction validation to generate recurring on-chain revenue and expand its digital asset strategy beyond treasury accumulation.
Dogwood Therapeutics entered into a subscription agreement to sell 4,098,360 shares of common stock to its largest shareholder, Sealbond Limited (a subsidiary of CK Life Sciences), in a $5 million private placement. The proceeds will be used to fund Phase 3 preparatory activities for Halneuron® and extend the company's operational runway through March 2027.
Bin Zhao, CEO, bought 17,345 shares of Agora, Inc. at $4.43 to $4.45 a share (average $4.44) in 2 transactions, worth $76.9K in total between Oct 15, 2026 and Oct 16, 2026. Shares held after the trade: 2,166,468 (+0.4%).
Atkore Inc. completed its merger with Prysmian S.p.A., with Atkore becoming a wholly owned subsidiary of Prysmian. Shareholders of Atkore received $95.00 in cash per share. In connection with the closing, Atkore terminated its existing credit facilities and redeemed $400 million of its 4.25% Senior Notes due 2031.
Eos Energy Enterprises announced preliminary Q3 2026 results, expecting revenue of $82M-$83M and a gross margin loss of 53%-55%. The company reported a backlog of $765M and total cash of $344M, driven by production scaling at its Thorn Hill facility and a $87M advance from its DOE loan facility.
Agassi Sports Entertainment $1M Debt Financing with Investments AKA, LLC
Agassi Sports Entertainment Corp. entered into an amendment to a $1.0 million convertible promissory note held by Investments AKA, LLC, an entity controlled by Andre Agassi. The amendment triggered the immediate conversion of the note's principal into 200,000 shares of common stock and 200,000 warrants at a conversion price of $5.00 per unit. This transaction effectively settles the existing debt obligation in exchange for equity securities.
Fuller H B Signs $1.4B M&A Deal with Ancora Holdings Group LLC
H.B. Fuller's Board of Directors unanimously rejected a second unsolicited, non-binding proposal from Ancora Holdings Group LLC to acquire the Company's Building Adhesive Solutions (BAS) business for $1.2 billion to $1.4 billion. The Board determined the offer undervalued the segment and lacked sufficient detail, though the Company will conduct a market check for select market segments and product lines by year-end 2026 to evaluate potential divestitures for deleveraging.
Mks Divestiture to TTM Technologies, Inc. for $650M
MKS Inc. has entered into a definitive agreement to sell its Ophir Optics business to TTM Technologies, Inc. for $650 million in cash. The transaction, which represents an 18x multiple of projected 2026 Adjusted EBITDA, is expected to close in the second quarter of 2027 and aims to strengthen MKS's balance sheet while focusing on its core semiconductor and electronics markets.
Teamshares $130M Debt Financing with Sound Point Agency LLC
Teamshares Inc. entered into a $130 million senior secured term loan facility with Sound Point Agency LLC to refinance a legacy $150 million credit facility. The new loan matures in October 2030 and carries an interest rate of one-month SOFR plus 9.50%. The refinancing is expected to reduce annual interest expense by approximately $5 million while addressing a near-term maturity.
Ttm Technologies Signs $650M M&A Deal with MKS Inc.
TTM Technologies has entered into a definitive agreement to acquire the Ophir Optics business from MKS Inc. for approximately $650 million in an all-cash transaction. The acquisition adds high-precision infrared thermal imaging and laser optics capabilities to TTM's defense and industrial portfolio and is expected to close in the second quarter of 2027.
Value
$650M
Counterparty
MKS Inc.
“We are excited to announce our planned acquisition of the Ophir Optics business as another important step toward enhancing our long-term growth strategy by expanding our portfolio with mission-critical optical solutions for land, air, maritime, and unmanned platforms and our industrial portfolio.”
DeFi Development Corp. reported its weekly treasury update, increasing its SOL holdings by 3,983 to a total of 2,590,266 SOL and SOL equivalents. The company also announced an increase in the annual dividend rate for its Series C Perpetual Preferred Stock (CHAD) from 13% to 14%, effective November 2, 2026.
Callan Jmb Deal Termination with The Pfanenstiel Company, LLC
Callan JMB Inc., through its subsidiary Callan Power LLC, has terminated its previously announced Asset Purchase and Sale Agreement with The Pfanenstiel Company, LLC. The company cited insufficient due diligence results as the reason for exercising its right to terminate the deal, which involved acquiring a 50% interest in oil and gas leases in North Dakota and Montana. As a result of the termination, the company no longer intends to raise the additional capital that would have been required to fund the acquisition.
Expand Energy Corporation appointed Daniel E. Brown as President and Chief Executive Officer, effective October 26, 2026. Mr. Brown's compensation package includes a $1,000,000 base salary, a 125% target bonus, and a make-whole equity award valued at approximately $15.65 million to compensate for forfeited compensation from his previous role at Chord Energy.
ArriVent BioPharma announced the publication of Phase 1b results for firmonertinib in the journal Cancer Cell, focusing on patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). The data showed a confirmed overall response rate (ORR) of 68% at the 240 mg dose and a median progression-free survival of 16.0 months, supporting the ongoing global Phase 3 ALPACCA trial.
Mattel, Inc. has appointed Peter Griffith as Chief Financial Officer and a member of the Board of Directors, effective October 20, 2026, succeeding Paul Ruh. Mr. Griffith's compensation package includes an annual base salary of $1,300,000, a 100% target bonus opportunity, and an inducement performance-based RSU award valued at $3,300,000. He also receives prorated 2026 and 2027 RSU grants totaling $3,500,000 as part of his new-hire agreement.
Silence Therapeutics has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for approximately $1.3 billion in cash. Under the terms of the deal, Silence shareholders will receive $20.00 per ADS, representing a 130% premium to the company's recent closing price. The acquisition aims to strengthen Merck KGaA's specialty and rare disease pipeline, specifically incorporating Silence's Phase 2 siRNA candidate, Divesiran.
Value
$1.3B
Counterparty
Merck KGaA, Darmstadt, Germany
“We are pleased to have reached this agreement with Merck KGaA, Darmstadt, Germany, which is the result of a competitive sale process and delivers significant, immediate and certain value to our shareholders.”
Iain Ross, Interim Principal Executive Officer and Chairman of the Silence Board
“The planned acquisition of Silence Therapeutics will strengthen our capabilities to serve patients with targeted specialty and rare diseases.”
Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany